LitCovid-sentences  

PMC:7736111 / 101531-104306 JSONTXT 2 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function

Id Subject Object Predicate Lexical cue
T597 0-64 Sentence denotes SARS-CoV-2 Antibody Cross-Reactivity and Neutralization Property
T598 65-149 Sentence denotes A range of SARS-CoV specific antibodies have shown cross-reactivity with SARS-CoV-2.
T599 150-234 Sentence denotes These antibodies target S protein and mostly the RBD region (Hoffmann et al., 2020).
T600 235-383 Sentence denotes Monoclonal antibodies against SARS-CoV such as CR3022 and S309 have shown cross-reactivity with SARS-CoV-2 (Pinto et al., 2020; Wang et al., 2020a).
T601 384-640 Sentence denotes Similarly, in a study of 285 patients, S protein-specific antibodies from SARS-CoV showed cross-reactivity with CoV-2 N protein in a subset of patients (n = 5), whereas no-cross reactivity was detected against S1 subunit of SARS-CoV-2 (Long et al., 2020a).
T602 641-758 Sentence denotes Thus, the cross-reactive nature of some of these antibodies may ensure their efficacy against multiple coronaviruses.
T603 759-901 Sentence denotes However, at the same time, these cross-reactive antibodies should also have neutralizing property; otherwise, they will have a harmful effect.
T604 902-1026 Sentence denotes A recent study explored the cross-reactive and neutralization property of these antibodies simultaneously (Lv et al., 2020).
T605 1027-1233 Sentence denotes This study used plasma from 15 SARS-CoV-2 and 7 SARS-CoV patients and found a high degree of cross-reactivity between the antibody response from these samples, but a very low antibody neutralizing property.
T606 1234-1315 Sentence denotes These results were further confirmed in animal models of SARS-CoV-2 and SARS-CoV.
T607 1316-1494 Sentence denotes While S309 antibody showed better neutralization property against SARS-CoV-2, the neutralization properties for CR3022 are not yet known (Pinto et al., 2020; Wang et al., 2020a).
T608 1495-1693 Sentence denotes Thus, although a high degree of cross-reactivity of the antibody response from SARS-CoV-2 can be found with other related CoVs, the neutralizing property of these antibodies may be epitope specific.
T609 1694-1920 Sentence denotes The weak neutralizing property of such cross-reactive antibodies should thoroughly be tested before usage as a therapeutic intervention, to prevent the complications which may arise due to antibody-dependent enhancement (ADE).
T610 1921-2003 Sentence denotes These factors also become essential while considering convalescent plasma therapy.
T611 2004-2121 Sentence denotes In an elegant recent study, Cao et al. (2020) performed sc-RNA-seq of B cells from 60 convalescent COVID-19 patients.
T612 2122-2246 Sentence denotes The study led to the identification of 14 neutralizing antibodies, among which one (BD-368-2) showed the most potent effect.
T613 2247-2377 Sentence denotes BD-368-2 was further explored for its efficacy in animal models and showed therapeutic potential in SARS-CoV-2 transgenic animals.
T614 2378-2618 Sentence denotes Further, the study suggested the use of two different monoclonal antibodies targeting different epitopes as a more viable therapeutic intervention than a single antibody, which is impressive considering the emerging mutations in SARS-CoV-2.
T615 2619-2775 Sentence denotes Thus, more research in this direction is needed to find antibodies with potent neutralization property for targeted therapy to alleviate the disease burden.